Rossi Francesca, Prosperini Luca, De Rossi Nicola, Capra Ruggero, Rivanera Daniela, Li Xiuhong, Cinque Paola, Passeri Laura, Pozzilli Carlo, Viscidi Raphael
1 Department of Public Health and Infectious Diseases, Sapienza University of Rome , Rome, Italy .
2 Department of Neurology and Psychiatry, Sapienza University of Rome , Rome, Italy .
Viral Immunol. 2017 Oct;30(8):622-626. doi: 10.1089/vim.2017.0039. Epub 2017 Aug 24.
To determine the association between BK polyomavirus (BKPyV) types 1 and 4 capsid antibody and natalizumab-associated progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), serum samples were obtained from 10 natalizumab-associated PML cases and 130 control MS patients treated with natalizumab, and 82 control MS patients never exposed to natalizumab. In a sex- and age-adjusted regression model, BKPyV serotype 1 antibody levels were significantly higher in natalizumab-treated controls (p = 0.009) compared with cases, and were higher in controls never treated with natalizumab compared with cases, but the difference did not reach statistical significance (p = 0.158). There was no association between BKPyV serotype 4 antibody and PML. We hypothesize that a robust immune response to BKPyV may be protective against the development of PML.
为确定1型和4型BK多瘤病毒（BKPyV）衣壳抗体与多发性硬化症（MS）患者中那他珠单抗相关的进行性多灶性白质脑病（PML）之间的关联，我们从10例那他珠单抗相关的PML病例、130例接受那他珠单抗治疗的对照MS患者以及82例从未接触过那他珠单抗的对照MS患者中获取了血清样本。在一项经性别和年龄调整的回归模型中，与病例相比，接受那他珠单抗治疗的对照中BKPyV 1型抗体水平显著更高（p = 0.009），与病例相比，从未接受那他珠单抗治疗的对照中该抗体水平也更高，但差异未达到统计学显著性（p = 0.158）。BKPyV 4型抗体与PML之间无关联。我们推测，对BKPyV的强大免疫反应可能对PML的发生具有保护作用。
